ArticleJournal of clinical microbiology2001
Evaluation of BACTEC Mycobacteria Growth Indicator Tube (MGIT 960) automated system for drug susceptibility testing of Mycobacterium tuberculosis.
Article in Journal of clinical microbiology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Current perspectives on drug susceptibility testing of Mycobacterium tuberculosis complex: the automated nonradiometric systems.Journal of clinical microbiology · 2006Pooled it
- Trial
- Clinical management of XpertBMC infectious diseases · 2026Observational
- Estimation of second line anti-tubercular drug susceptibility toIranian journal of microbiology · 2025Article
- CRISPR for companion diagnostics in low-resource settings.Lab on a chip · 2024Review
- Multi-drug resistant gene mutation analysis inIranian journal of microbiology · 2024Article
- Drug Susceptibility and Mutation Profiles in Mycobacterium tuberculosis Isolates from a Tertiary Care Hospital in Kerala, India.The American journal of tropical medicine and hygiene · 2024Article
- Combination of gallium citrate and levofloxacin induces a distinct metabolome profile and enhances growth inhibition of multidrug-resistantFrontiers in microbiology · 2024Article
- Epidemiology of multi-drug resistant Tuberculosis in the western region of Kenya.AIMS microbiology · 2024Article
- Oxygen Sensor-Based Respirometry and the Landscape of Microbial Testing Methods as Applicable to Food and Beverage Matrices.Sensors (Basel, Switzerland) · 2023Review
- Tuberculosis/COVID-19 co-infection detected in a single sputum sample using a rapid molecular test.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2022Article
- Reevaluating Rifampicin Breakpoint Concentrations for Mycobacterium tuberculosis Isolates with DisputedMicrobiology spectrum · 2022Article
- Performance of WHO-Endorsed Rapid Tests for Detection of Susceptibility to First-Line Drugs in Patients with Pulmonary Tuberculosis in Bangladesh.Diagnostics (Basel, Switzerland) · 2022Article
- Neuro-ophthalmic manifestations of tuberculosis.Eye (London, England) · 2022Review
- Rapid Molecular Assays for the Diagnosis of Drug-Resistant Tuberculosis.Infection and drug resistance · 2022Review
- Ensemble density-dependent synchronization of mycobacterial growth: BACTEC MGIT 960 fluorescence-based analysis and mathematical modelling of coupled biophysical and chemical processes.AIMS microbiology · 2022Article
- Drug resistantPeerJ · 2022Article
- Molecular epidemiology and multidrug resistance ofHeliyon · 2021Article
- 1,3-Diarylpyrazolyl-acylsulfonamides as Potent Anti-tuberculosis Agents Targeting Cell Wall Biosynthesis inJournal of medicinal chemistry · 2021Article
- Revisiting the methods for detectingAccess microbiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The reliability of the BACTEC MGIT 960 system, an automated version of the Mycobacteria Growth Indicator Tube (MGIT), for antimicrobial susceptibility testing of Mycobacterium tuberculosis was evaluated on 78 clinical isolates. Rifampin (RMP), isoniazid (INH), streptomycin (SM), and ethambutol (EMB) were tested at the following concentrations: 1.0 microg/ml for RMP, 0.1 and 0.4 microg/ml for INH, 1.0 and 4.0 microg/ml for SM, and 5.0 and 7.5 microg/ml for EMB. Results were compared with those obtained by the BACTEC 460 TB radiometric system. Initially the reproducibility study showed 99.5% agreement on repeat testing with all the four drugs. With susceptibility testing of clinical isolates, excellent agreement between the two systems was found for all the drugs. A total of nine major errors were observed for only three isolates, resistant according to BACTEC MGIT 960 and susceptible according to BACTEC 460 TB, to SM (4.0 microg/ml), INH (0.1 microg/ml), and EMB (5.0 microg/ml) (one isolate) and to SM (1.0 microg/ml), INH (0.4 microg/ml), and EMB (5.0 microg/ml) (two isolates). When these isolates were tested by using the conventional proportion method on Löwenstein-Jensen medium, agreement with BACTEC MGIT 960 was found for five results and with BACTEC 460 TB for the remainder. The time to report results was 7.9 days by MGIT 960 and 7.3 days by BACTEC 460 TB, which was not found statistically significant (P > 0.05). In conclusion, the performance of BACTEC MGIT 960 was found similar to that of BACTEC 460 TB and this new system can be considered a good alternative to the radiometric method for routine susceptibility testing of M. tuberculosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.